Neuro-Behavioral Clinical Research | North Canton, OH
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar (nM). Optional healthy older participants (Part 2) may receive MK-2214 at dose levels determined by criteria met in Part 1.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Part 1 (MCI and Mild to Moderate AD) Only:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
48 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Toll Free Number
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal